This is Part I of our special report on the state of immunotherapy in the public markets. This report looks at promising anticancer immunotherapy technologies, and the major issues in bringing these technologies to the general public.
HealthTech Conference 2012, on October 26th in San Francisco, is a single day summit covering the most important issues in this burgeoning sector. OneMedRadio spoke with Anne Degheest, Managing Director and Founder of HealthTech Capital, about conference programming, and the unique investment opportunity in the sector.
Implandata Ophthalmic Products GmbH, a German medical device start-up developing a technology for monitoring chronic eye diseases such as glaucoma, will be featured among the private companies presenting at the 6th Annual OneMedForum, January 7-9 in San Francisco.
Dear Readers, What an exciting week in our sector. Our Sentinel this week focuses on a handful of companies with powerful technology. Our “above the […]
The threat of infection in hospital and other treatment facilities have dramatically increased over the last few years. Antibiotics and other therapies have become impotent against certain pathogens and infections, increasing the need for research funding for creating new antibiotics. These three companies have the potential to solve a significant unmet medical need.
OneMedRadio spoke with Ray Briscuso, Managing Partner and Producer of AdvaMed 2012, to learn about the can’t miss highlights in conference programming. Briscuso also discussed the history of the conference — how a gathering once geared toward trade association types has grown into one of the most important events in facilitating growth company finance in the sector.
The 6th Annual AdvaMed 2012 MedTech Conference kicks off October 1st for a 3-day event covering the hottest issues in the sector. This year, AdvaMed expects more than 2,100 attendees, 800 MedTech companies from 24 countries, 36 states and DC.
Santarus, Inc. expects an FDA decision under the Prescription Drug User Fee Act (PDUFA) on the approval status of UCERIS, being developed for the treatment […]
Supernus Pharmaceuticals [Nasdaq: SUPN] expects an FDA decision under the Prescription Drug User Fee Act (PDUFA) on the approval status of SPN-804, being developed for […]
The San Diego-based pharmaceutical company has five approved products internationally, covering erectile dysfunction (Vitaros), side effects of cancer therapy (Totect and Granisol), coronary artery disease (Nitromist) and dry mouth (Aquoral). After a series of successes in strategic partnerships, acquisitions, peer review and clinical data in Q3, the company is garnering some serious attention.
Copyright © 2024 | WordPress Theme by MH Themes